These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33554879)

  • 1. Long non-coding RNA (lncRNA) DSCAM-AS1 is upregulated in breast cancer.
    Tarighi M; Khalaj-Kondori M; Hosseinzadeh A; Abtin M
    Breast Dis; 2021; 40(2):63-68. PubMed ID: 33554879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of the long noncoding RNAs DSCAM-AS1 and MANCR is a potential diagnostic marker for breast carcinoma.
    Tahmouresi F; Razmara E; Pakravan K; Mossahebi-Mohammadi M; Rouhollah F; Montazeri M; Sarrafzadeh A; Fahimi H; Babashah S
    Biotechnol Appl Biochem; 2021 Dec; 68(6):1250-1256. PubMed ID: 33012018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DSCAM-AS1 up-regulation in invasive ductal carcinoma of breast and assessment of its potential as a diagnostic biomarker.
    Khorshidi H; Azari I; Oskooei VK; Taheri M; Ghafouri-Fard S
    Breast Dis; 2019; 38(1):25-30. PubMed ID: 30594914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer.
    Ma Y; Bu D; Long J; Chai W; Dong J
    J Cell Physiol; 2019 Mar; 234(3):2880-2894. PubMed ID: 30203615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical significance of circulating DSCAM-AS1 in patients with ER-positive breast cancer and construction of its competitive endogenous RNA network.
    Moradi MT; Fallahi H; Rahimi Z
    Mol Biol Rep; 2020 Oct; 47(10):7685-7697. PubMed ID: 33040318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
    Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
    Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
    [No Abstract]   [Full Text] [Related]  

  • 7. Long noncoding RNA DSCAM-AS1 functions as an oncogene in non-small cell lung cancer by targeting BCL11A.
    Liao J; Xie N
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1087-1092. PubMed ID: 30779076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA DSCAM-AS1 is associated with poor clinical prognosis and contributes to melanoma development by sponging miR-136.
    Huang YL; Xu Q; Wang X
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2888-2897. PubMed ID: 31002140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2.
    Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH
    Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA DSCAM-AS1 indicates a poor prognosis and modulates cell proliferation, migration and invasion in ovarian cancer via upregulating SOX4.
    Li Y; Hao J; Jiang YM; Liu Y; Zhang SH
    Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4143-4148. PubMed ID: 31173284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression analysis of vimentin and the related lncRNA network in breast cancer.
    Mohebi M; Ghafouri-Fard S; Modarressi MH; Dashti S; Zekri A; Kholghi-Oskooei V; Taheri M
    Exp Mol Pathol; 2020 Aug; 115():104439. PubMed ID: 32283061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer.
    El-Ashmawy NE; Hussien FZ; El-Feky OA; Hamouda SM; Al-Ashmawy GM
    Life Sci; 2020 Oct; 259():118193. PubMed ID: 32763293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.
    Niknafs YS; Han S; Ma T; Speers C; Zhang C; Wilder-Romans K; Iyer MK; Pitchiaya S; Malik R; Hosono Y; Prensner JR; Poliakov A; Singhal U; Xiao L; Kregel S; Siebenaler RF; Zhao SG; Uhl M; Gawronski A; Hayes DF; Pierce LJ; Cao X; Collins C; Backofen R; Sahinalp CS; Rae JM; Chinnaiyan AM; Feng FY
    Nat Commun; 2016 Sep; 7():12791. PubMed ID: 27666543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role and clinical significance of long noncoding RNA zinc finger E-box-binding homeobox two antisense RNA 1 in promoting osteosarcoma cancer cell proliferation, inhibiting apoptosis and increasing migration by regulating miR-145.
    Zhou Y; Feng D; Gu X; Gao A; Liu Y
    Anticancer Drugs; 2021 Feb; 32(2):168-177. PubMed ID: 32826416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone modulates the DSCAM-AS1/miR-130a/ESR1 axis to suppress cell invasion and migration in breast cancer.
    Yadav N; Sunder R; Desai S; Dharavath B; Chandrani P; Godbole M; Dutt A
    Breast Cancer Res; 2022 Dec; 24(1):97. PubMed ID: 36578092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA DSCAM-AS1 promotes non-small cell lung cancer progression via regulating miR-577/HMGB1 axis.
    Qiu Z; Pan XX; You DY
    Neoplasma; 2020 Jul; 67(4):871-879. PubMed ID: 32386483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA DSCAM-AS1 promoted cell proliferation and invasion in osteosarcoma by sponging miR-101.
    Yu CL; Xu NW; Jiang W; Zhang H; Ma Y
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7709-7717. PubMed ID: 32744697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA DSCAM-AS1: A Pivotal Therapeutic Target in Cancer.
    Hu C
    Mini Rev Med Chem; 2023; 23(5):530-536. PubMed ID: 35996247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer.
    Ma D; Chen C; Wu J; Wang H; Wu D
    Breast Cancer; 2019 Jan; 26(1):74-83. PubMed ID: 29974352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA HNF1A-AS1 indicates a poor prognosis of colorectal cancer and promotes carcinogenesis via activation of the Wnt/β-catenin signaling pathway.
    Zhang X; Xiong Y; Tang F; Bian Y; Chen Y; Zhang F
    Biomed Pharmacother; 2017 Dec; 96():877-883. PubMed ID: 29145164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.